Clinical Trials
2
Active:1
Completed:0
Trial Phases
2 Phases
Phase 2:1
Phase 4:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Phase 2
1 (50.0%)Phase 4
1 (50.0%)Efficacy and Safety of Standard of Care Plus Durvalumab in Patients with Limited Disease Small Cell Lung Cancer (DOLPHIN)
Phase 2
Recruiting
- Conditions
- Small Cell Lung Cancer Limited Stage
- Interventions
- Drug: standard of care
- First Posted Date
- 2020-10-26
- Last Posted Date
- 2025-03-26
- Lead Sponsor
- Michael Hopp
- Target Recruit Count
- 105
- Registration Number
- NCT04602533
- Locations
- 🇩🇪
Klinik Löwenstein gGmbH, Löwenstein, Baden-Würtemberg, Germany
🇩🇪Klinikverbund Allgäu gGmbH, Immenstadt, Bayern, Germany
🇩🇪Asklepios Fachkliniken Muenchen Gauting, München Gauting, Bayern, Germany
AFAMOSI: Efficacy and Safety of Afatinib Followed by Osimertinib Compared to Osimertinib in Patients with EGFRmutated/T790M Mutation Negative Nonsquamous NSCLC
Phase 4
Active, not recruiting
- Conditions
- Non-squamous NSCLC
- Interventions
- First Posted Date
- 2020-06-02
- Last Posted Date
- 2025-03-25
- Lead Sponsor
- Michael Hopp
- Target Recruit Count
- 34
- Registration Number
- NCT04413201
- Locations
- 🇩🇪
Klinikum der Ludwig-Maximilians-Universität München, München, Bayern, Germany
🇩🇪Universitätsklinikum Gießen Marburg, Gießen, Hessen, Germany
🇩🇪Sana-Klinikum Offenbach, Offenbach, Hessen, Germany
News
No news found